Skip to main content

SINTX Technologies

HardwareSalt Lake City, United StatesFounded 1996· One of 1708 Hardware companies tracked by AMPulse

SINTX Technologies is an advanced ceramics manufacturer and medical device company that develops proprietary silicon nitride biomaterials for spinal fusion, orthopedic implants, and antimicrobial applications.

CEO / Founder
Eric K. Olson
Team Size
11-50
Stage
Active
Total Funding
$122.0M
Latest Round
Post-IPO
Key Investors
Creation Capital LLC, Hercules Technology Growth Capital, Zions Bank, MG Partners II Ltd. (Magna)

Technology & Products

Key Products

["Spinal Interbody Fusion Devices (Cervical & Lumbar)","SINAPTIC® Foot & Ankle Implant System","Silicon Nitride Osteotomy Wedges","Silicon Nitride-PEEK (SiN/PEEK) Composite Materials","Antipathogenic Silicon Nitride Powder","Hybrid CFR-PEKK Trauma Plates","AI-Assisted 3D-Printed Patient-Specific Implants"]

Technological Advantage

Vertically integrated 30,000 sq. ft. manufacturing facility enabling rapid prototyping and product development; silicon nitride's unique combination of osteogenic (bone-forming), antibacterial, antifungal, and antiviral properties creates multi-functional biomaterial platform; AI-assisted 3D printing capabilities for patient-specific implants through EVONIK partnership

Differentiation

Value Proposition

Silicon nitride biomaterials that combine superior bone fusion properties with inherent antibacterial and antiviral characteristics, reducing infection risk while promoting faster healing compared to traditional PEEK or titanium implants

How They Differentiate

Only FDA-registered silicon nitride medical device manufacturer globally; proprietary silicon nitride biomaterial with unique combination of osteogenic (bone-forming), antibacterial, antifungal, and antiviral properties; demonstrated 99.97% viral reduction against coronaviruses; vertically integrated 30,000 sq. ft. manufacturing facility

Market & Competition

Target Customers

Orthopedic and spinal surgeons, hospitals, ambulatory surgery centers, medical device OEM partners, and patients requiring spinal fusion or orthopedic implant procedures

Industry Verticals

["Medical Devices & Orthopedics","Spine Surgery","Advanced Ceramics Manufacturing","Biomaterials","Infection Prevention","Industrial Ceramics"]

Competitors

Zimmer Biomet; Kyocera Corporation; CoorsTek

Growth & Milestones

Growth Metrics

Publicly traded on NASDAQ (SINT) since February 2014; $2.89M annual revenue (Dec 2024); over 50,000 spinal implants successfully deployed since 2008; market cap of $8.4M (Aug 2025)

Major Milestones

["Completed IPO on NASDAQ in February 2014 (as Amedica Corporation)","Over 50,000 silicon nitride spinal implants deployed since 2008","FDA clearance for SINAPTIC® Foot & Ankle Implant System (Oct 2025)","Supply agreement with EVONIK for AI-assisted 3D-printed patient-specific implants (Dec 2025)","Demonstrated 99.97% viral reduction against SARS-CoV-2 (2020)","Acquired SiNAPTIC Surgical for orthopedic expansion (Jul 2025)","Acquired Technology Assessment & Transfer (TA&T) advanced ceramics R&D company (2026)"]

Notable Customers

CTL/Amedica (exclusive spinal implant distribution); EVONIK (SiN/PEEK compound manufacturing partnership); Oxford Performance Materials (joint coating development)

https://sintx.com

Why this company matters

SINTX Technologies occupies a narrow but defensible position as the only FDA-registered manufacturer of silicon nitride medical devices globally. Its proprietary biomaterial platform addresses a persistent clinical trade-off in spinal and orthopedic surgery: traditional PEEK implants are bioinert and prone to infection, while titanium offers strength but lacks osteogenic activity. Silicon nitride bridges that gap by promoting bone formation while exhibiting antibacterial, antifungal, and antiviral properties, including a demonstrated 99.97% viral reduction against SARS-CoV-2.

The company operates a vertically integrated 30,000 sq. ft. manufacturing facility in Salt Lake City that supports rapid prototyping and product development across multiple modalities. Its product portfolio includes spinal interbody fusion devices (cervical and lumbar), the SINAPTIC Foot & Ankle Implant System (FDA-cleared October 2025), silicon nitride osteotomy wedges, and SiN/PEEK composite materials. Through a December 2025 supply agreement with Evonik, SINTX is developing AI-assisted 3D-printed patient-specific implants, combining its silicon nitride expertise with Evonik's polymer compounding capabilities.

SINTX targets orthopedic and spinal surgeons, hospitals, ambulatory surgery centers, and medical device OEM partners. Over 50,000 silicon nitride spinal implants have been deployed since 2008. The company is transitioning from an OEM spinal implant supplier to direct commercialization, with expansion into foot and ankle reconstruction following the July 2025 acquisition of SiNAPTIC Surgical. Key partnerships include CTL/Amedica for exclusive spinal implant distribution and Oxford Performance Materials for joint coating development.

Competitive risks include the entrenched positions of Zimmer Biomet, Kyocera, and CoorsTek in conventional ceramics and metal implants. SINTX's market cap of $8.4 million (August 2025) and $2.89 million in annual revenue (December 2024) reflect its small scale relative to these competitors. The company's moat rests on its proprietary silicon nitride processing IP and the regulatory barrier of being the sole FDA-registered silicon nitride medical device facility. Whether the antimicrobial and osteogenic advantages translate into sufficient surgeon adoption to drive revenue growth remains the central open question.